Pancuronium pandemonium as doctors slam Hospira for execution injections
This article was originally published in Scrip
Executive Summary
An open letter published in the Lancet has criticised Hospira for its handling of the use of its muscle relaxant pancuronium bromide in executions in the US. However, Lundbeck, which faced a similar issue with its drug pentobarbital (Nembutal) for acute convulsive disorders, has emerged with its reputation intact. The letter praises the firm for its "truly exemplary" response to the situation after it tightened distribution of the drug.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.